Impact of IL28B and OAS gene family polymorphisms on interferon treatment response in Caucasian children chronically infected with hepatitis B virus

Table 3 Impact of clinical and genetic factors on partial response in HBeAg-negative chronic hepatitis B children

Characteristic	CR,	No-CR,	P value	OR (95%CI)
	n = 22	n = 30
Age (yr)
Median (range)	16 (12-18)	17 (4-18)	0.141
Gender
Female	8 (36.4)	8 (26.7)	0.454
Staging (F)
F0-F1	14 (63.6)	19 (63.3)	0.942
Grading (A)
A0-A1	10 (45.5)	15 (50.0)	0.746
Baseline HBV DNA (IU/mL)
Median (range), log	4.6 (3.4-8.0)	4.7 (3.5-8.0)	0.671
< 20000	14 (63.6)	17 (56.7)	0.613
Baseline ALT (U/L)
Median (range)	43 (10-110)	48 (17-126)	0.116
< 40	8 (36.3)	6 (20.0)	0.189
IL28B rs12979860
CC	8 (36.4)	12 (40.0)	0.790
CT	14 (63.6)	12 (40.0)
TT	0 (0.0)	6 (20.0)	0.033	NA
IL28B rs12980275
AA	11 (50.0)	13 (43.3)	0.634
AG	11 (50.0)	13 (43.3)
GG	0 (0.0)	4 (13.4)	0.128
IL28B rs8099917
TT	15 (68.2)	15 (50.0)	0.190
TG	7 (31.8)	12 (40.0)
GG	0 (0.0)	3 (10.0)	0.253
OASL rs10849829
AA	5 (22.7)	16 (53.3)	0.026	0.26 (0.07-0.88)
AG	14 (63.6)	11 (36.7)
GG	3 (13.6)	3 (10.0)	0.685
OAS1 rs1131476
AA	10 (45.5)	16 (53.3)	0.575
AG	8 (36.4)	9 (30.0)
GG	4 (18.1)	5 (16.7)	0.887
OAS2 rs1293747
GG	14 (63.6)	18 (60.0)	0.253
GA	8 (36.4)	9 (30.0)
AA	0 (0.0)	3 (10.0)	0.790
OAS3 rs2072136
GG	15 (68.2)	15 (50.0)	1.000
GA	6 (27.3)	14 (46.7)
AA	1 (4.5)	1 (3.3)	0.190

Data are presented as the number of patients (%) unless otherwise indicated. NA: Not applicable.